摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Diisopropyl ether-hexane

中文名称
——
中文别名
——
英文名称
Diisopropyl ether-hexane
英文别名
isopropyl ether - hexane;7-Methyl-1-propan-2-yloxyoctane
Diisopropyl ether-hexane化学式
CAS
——
化学式
C12H26O
mdl
——
分子量
186.338
InChiKey
OXJWJTYJTZJRDN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.5
  • 重原子数:
    13
  • 可旋转键数:
    8
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    9.2
  • 氢给体数:
    0
  • 氢受体数:
    1

反应信息

点击查看最新优质反应信息

文献信息

  • Quinone derivatives, their production and use
    申请人:Takeda Chemical Industries, Ltd.
    公开号:US05180742A1
    公开(公告)日:1993-01-19
    Quinone derivatives of the general formula: ##STR1## (wherein R.sup.1 and R.sup.2 are the same or different, and independently are a hydrogen atom or a methyl or methoxy group, or R.sup.1 and R.sup.2 combine with each other to represent --CH.dbd.CH--CH.dbd.CH--R.sup.3 is a hydrogen atom or a methyl group; R.sup.4 is an aliphatic, aromatic or heterocyclic group which may be substituted; R.sup.5 is a methyl or methoxy group, a hydroxymethyl group which may be substituted or a carboxyl group which may be esterified or amidated; Z is a group represented by --C.dbd.C--, --CH.dbd.CH--, ##STR2## n is an integer of 0 to 10; m is an integer of 0 to 3; k is an integer of 0 to 5, provided, however, that in the case of m being 2 or 3, Z and k can vary arbitrarily within the bracketed repeating units) are novel compounds, possess metabolism ameliorating action for polyunsaturated fatty acids, particularly production inhibitory activity of lipid peroxides (antioxidant activity), thromboxane A.sub.2 receptor antagonism, or production inhibitory activity of 5-lipoxygenase metabolites in mammals, and of use as drugs, such as antiasthmatic, antiallergic agent and cerebral-circulatory metabolism ameliorating agent.
    通式为:##STR1##的醌衍生物(其中R.sup.1和R.sup.2相同或不同,且独立地为氢原子或甲基或甲氧基,或R.sup.1和R.sup.2结合在一起表示--CH.dbd.CH--CH.dbd.CH--R.sup.3为氢原子或甲基;R.sup.4为可以被取代的脂肪、芳香或杂环基团;R.sup.5为甲基或甲氧基、可以被取代的羟甲基或可以酯化或酰胺化的羧基;Z为--C.dbd.C--,--CH.dbd.CH--,##STR2##所表示的基团;n为0到10的整数;m为0到3的整数;k为0到5的整数,但是在m为2或3的情况下,Z和k可以在括号内的重复单元中任意变化)是新颖的化合物,具有改善多不饱和脂肪酸代谢的作用,特别是对脂质过氧化物的产生抑制活性(抗氧化活性)、血栓素A.sub.2受体拮抗作用,或对哺乳动物中5-脂氧合酶代谢产物的产生抑制活性,并可用作药物,如抗哮喘、抗过敏剂和改善脑循环代谢的药剂。
  • [EN] COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY<br/>[FR] COMPOSÉS AYANT UNE ACTIVITÉ ANTAGONISTE D'UN RÉCEPTEUR MUSCARINIQUE ET AGONISTE D'UN RÉCEPTEUR BÊTA2 ADRÉNERGIQUE
    申请人:CHIESI FARMA SPA
    公开号:WO2012168359A1
    公开(公告)日:2012-12-13
    The present invention relates to compounds acting both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists, to processes for their preparation, to compositions comprising them, to therapeutic uses and combinations with other pharmaceutical active ingredients.
    这项发明涉及既作为肌肉胆碱受体拮抗剂又作为β2肾上腺素受体激动剂的化合物,涉及它们的制备方法,包含它们的组合物,治疗用途以及与其他药用活性成分的组合。
  • Tricyclic condensed heterocyclic compounds, their production and use
    申请人:Takeda Chemical Industries, Ltd.
    公开号:US05527800A1
    公开(公告)日:1996-06-18
    A novel compound of the formula: ##STR1## wherein Ar represents an optionally substituted tricyclic condensed benzene ring group which includes at least one heterocyclic ring as a component ring; n represents an integer from 2 to 10; R.sup.1 represents H or an optionally substituted hydrocarbon group, which may be different from one another in the repetition of n; and Y represents an optionally substituted 4-piperidinyl, 1-piperazinyl or 4-benzyl-1-piperidinyl group, or a salt thereof, inhibiting excellent cholinesterase inhibitory activity and monoamine reuptake inhibitory activity, thus being useful as therapeutic and/or prophylactic medicaments of senile dementia.
    一种化合物的式子:##STR1## 其中Ar代表一个可选择取代的三环融合苯环基团,其中至少包含一个杂环环作为组成环;n代表一个从2到10的整数;R.sup.1代表H或一个可选择取代的烃基团,可能在n的重复中彼此不同;Y代表一个可选择取代的4-哌啶基、1-哌嗪基或4-苄基-1-哌啶基团,或其盐,抑制优异的胆碱酯酶抑制活性和单胺再摄取抑制活性,因此可用作治疗和/或预防老年性痴呆症的药物。
  • Tricyclic oxindole antiinflammatory agents
    申请人:Pfizer Inc.
    公开号:US04695571A1
    公开(公告)日:1987-09-22
    Tricyclic oxindole carboxamides, prepared by (a) reaction of an isocyanate with the basic ring system or (b) ammonolysis of a corresponding alkyl ester, are non-steroidal antiinflammatory agents useful in the treatment of rheumatoid arthritis.
    三环氧吲哚羧酰胺,通过以下两种方法制备:(a)异氰酸酯与碱性环系统的反应,或者(b)对应的烷基酯的氨解反应。这些化合物是非类固醇抗炎药,可用于治疗类风湿性关节炎。
  • EP703222
    申请人:——
    公开号:——
    公开(公告)日:——
查看更多